Candesartan Cilexetil Articles
AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million
2 March 2010
Japan stock market week to March 23, 2009
30 March 2009
PDCO confirms refusal of PIPs for Takeda and AZ
23 February 2009
AZ gets nod in EU for two new Atacand doses
16 February 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
Japan stock market week to Sept 22, 2008
29 September 2008
ARB switching strategy may not result in long-term savings within a five-year model, says Merck & Co
12 May 2008
Merck & Co sells JV products to AZ
10 March 2008
Japan stock market week to February 4 , 2008
14 February 2008
Takeda set for $18.5B sales 2015, R&I says
28 January 2008
Takeda's income for fiscal 1st half grows 37%
19 November 2007
Japan stock market week to September 3, 2007
10 September 2007
Japan stock market week to July 24, 2006
26 July 2006
Japan stock market week to July 17, 2006
24 July 2006
AstraZeneca's Atacand "complements ACEs"
15 May 2006
TROPHY study: strong results for Atacand
1 May 2006
Takeda 's income rises 14.4% in 1st 3 fiscal qtrs
20 February 2006
AstraZeneca's heart drug Atacand also reduces diabetes risk
12 September 2005
Takeda's 1st-qtr stronger-than-expected due to volume growth
15 August 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Atacand cuts diabetes risk in HF patients
11 July 2005
Good patient reports on AstraZeneca's Atacand
4 July 2005
CHARM: new analysis shows Atacand benefit
13 June 2005
Japan stock market week to May 30
6 June 2005
Biovail gets tentative FDA OK for generic Ambien
6 June 2005
Expanded indication for AstraZeneca's Atacand
30 May 2005
Japan stock market week to February 28
7 March 2005
FDA clears new use for AstraZeneca's Atacand
28 February 2005
Strong 3rd-qtr for Takeda, as Actos and candesartan expand globally
21 February 2005
Japan stock market week to February 7
14 February 2005
AstraZeneca's EPS up 56%, sales rise 10%
1 November 2004
Tokyo pharma stocks - 2 weeks to August 30
6 September 2004
New dose of Atacand cleared in EU
23 August 2004
Tokyo pharma stocks - week to June 21
28 June 2004
Tokyo pharma stocks - week to May 24
31 May 2004
AstraZeneca files Atacand in the UK
12 April 2004
Stock Commentary - Tokyo
22 March 2004
Tokyo pharma stocks - week to March 15
22 March 2004
AstraZeneca-sponsored candesartan trial results
15 March 2004
New data on candesartan cilexetil
15 March 2004
AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales
9 February 2004
Sankyo's Mevalotin retains number one spot in Japan
2 February 2004
Atacand reduces stroke in elderly with ISH
17 November 2003
Stock Commentary - Europe
15 September 2003
Encouraging results for AstraZeneca on Exanta and Atacand
8 September 2003
Stock Commentary - Europe
8 September 2003
Tokyo pharma stocks - week to July 28
4 August 2003
Correction: AstraZeneca's Atacand
28 July 2003
Stroke patients benefit early use of Atacand
14 July 2003
Takeda forecasts 315B yen profit in 2004
28 April 2003
Robust Takeda faces growing competition
13 January 2003
Atacand of value in migraine?
6 January 2003
AstraZeneca sales rise 6.9% in 2nd quarter
5 August 2002
Atacand comparative claim backed by FDA panel
29 July 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Atacand cuts mortality in stroke patients
6 December 2001
"Robust" year for AstraZeneca
5 December 2001
UK hypertension care in the elderly debated
7 November 2001
AstraZeneca completes TROPHY enrollment
14 August 2001
AstraZeneca sales rise 8%, Nexium doing well
26 July 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
Clarification: diabetic retinopathy treatment
18 January 2001
AstraZeneca launches retinopathy trial
6 November 2000
AstraZeneca wins US OK for Atacand HCT
6 September 2000
New study shows similar efficacy of AIIRAs
11 May 2000
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
